Abstract Dipeptidyl peptidase 4 (DPP4), also known as CD26 is a type II transmembrane
protein that is released from the cell membrane in a nonclassical secretory mechanism. This …

Abstract Dipeptidyl-peptidase-4 (DPP-4) is an enzyme having various properties and
physiological roles in lipid accumulation, resistance to anticancer agents, and immune …

A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study was
conducted to evaluate the efficacy of treatment with ipragliflozin (sodium‐dependent glucose …

Abstract Aims/Introduction Recent randomized clinical trials have suggested that sodium–
glucose cotransporter 2 inhibitors might reduce cardiovascular events and heart failure, and …

Both high glucose intake with a high-fat meal and inhibition of dipeptidyl peptidase-4 (DPP4)
have been associated with plasma lipid-lowering effects, but mechanistic understanding …

Objective To investigate the effect of add-on exenatide to insulin on glycemic excursion and
the counter-regulatory hormone in response to hypoglycemia in patients with type 1 …

Hypertension and type 2 diabetes mellitus (DM) are among the main risk factors for the
development of cardiovascular disease. Pharmacotherapy for DM should not only improve …

Introduction In Japan, dipeptidyl peptidase-4 (DPP-4) inhibitors are frequently used as the
treatment of choice for patients with type 2 diabetes. In some cases, however, poor …

Despite recent advances in medical research, the incidence of diabetes and cardiovascular
disease (CVD)-induced fatal events is increasing. The literature point towards several co …

SUMMARY Dipeptidyl peptidase 4 (DPP4) is a proteolytic enzyme, involved in a wide range
of different cellular functions and expressed on the surface of most cell types, including the …